Effectiveness of a systematic vaccination program in patients with autoimmune inflammatory disease treated with anti-TNF alpha drugs

Fernandez-Martinez, Sergio; Cortés, Xavier; Borrás-Blasco, Joaquı́n; Gracia-Pérez, Antonio; Mora, Elvira

doi:10.1080/14712598.2016.1218844

Cited by 9 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vaccination prevents infections by inducing and/or enhancing protective immunity. Vaccination is particularly important in AIIRD patients, potentially translating into a lower rate of hospital admissions due to infections, emergency room visits and the rate of invasive infectious diseases 11. Yet, the AIIRD population universally suffers from a suboptimal uptake of vaccinations,12–19 in part due to a low rate of referral for vaccination by rheumatologists20 and other treating physicians,21 indicating that further interventions are needed to raise the awareness for vaccination among the rheumatology community and involved healthcare professionals.…”

Section: Introductionmentioning

confidence: 99%

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Furer

Rondaan

Heijstek

et al. 2020

Annals of the Rheumatic Diseases

615

531

View full text Add to dashboard Cite

To update the European League Against Rheumatism (EULAR) recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) published in 2011. Four systematic literature reviews were performed regarding the incidence/prevalence of vaccine-preventable infections among patients with AIIRD; efficacy, immunogenicity and safety of vaccines; effect of anti-rheumatic drugs on the response to vaccines; effect of vaccination of household of AIIRDs patients. Subsequently, recommendations were formulated based on the evidence and expert opinion. The updated recommendations comprise six overarching principles and nine recommendations. The former address the need for an annual vaccination status assessment, shared decision-making and timing of vaccination, favouring vaccination during quiescent disease, preferably prior to the initiation of immunosuppression. Non-live vaccines can be safely provided to AIIRD patients regardless of underlying therapy, whereas live-attenuated vaccines may be considered with caution. Influenza and pneumococcal vaccination should be strongly considered for the majority of patients with AIIRD. Tetanus toxoid and human papilloma virus vaccination should be provided to AIIRD patients as recommended for the general population. Hepatitis A, hepatitis B and herpes zoster vaccination should be administered to AIIRD patients at risk. Immunocompetent household members of patients with AIIRD should receive vaccines according to national guidelines, except for the oral poliomyelitis vaccine. Live-attenuated vaccines should be avoided during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy. These 2019 EULAR recommendations provide an up-to-date guidance on the management of vaccinations in patients with AIIRD.

show abstract

Section: Introductionmentioning

confidence: 99%

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Furer

Rondaan

Heijstek

et al. 2020

Annals of the Rheumatic Diseases

615

531

View full text Add to dashboard Cite

show abstract

“…Vaccination is known to reduce rates of hospital admissions due to infections, emergency room visits, and the rate of invasive infectious diseases in patients with autoimmune disease. 7 However, it has been extensively demonstrated that anti-CD 20 therapy (both rituximab and ocrelizumab) is associated with impaired vaccine response. This was first demonstrated in patients with neuromyelitis optica on rituximab therapy, with reduction in protective antibody titer and seroconversion rate (37.5% vs. 75.0% healthy controls) post-H1N1 influenza A vaccination.…”

mentioning

confidence: 99%

Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists

Kant¹,

Kronbichler²,

Salas³

et al. 2021

Kidney International Reports

View full text Add to dashboard Cite

“… 30 When possible, patients should be adequately vaccinated and closely monitored for early signs of infection. 42 …”

Section: Infection Suspicion and Diagnosis In Patients Taking Biologimentioning

confidence: 99%

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables

Niccoli

Nannini

Blandizzi

et al. 2018

TCRM

View full text Add to dashboard Cite

ObjectiveTo propose appropriate statements that drive the choice of biologic therapies in patients with rheumatoid arthritis (RA), factoring in their impact on the following issues: anti-drug antibody (ADAb) formation, suspicion and management of infections, lupus-like syndrome (LLS), effects on bone mass and sexual sphere, and relationship between RA and periodontal disease (PD).MethodsAn overview of existing evidence was undertaken by an expert panel on behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO). Data were extracted from controlled trials, national registries, national health care databases, post-marketing surveys, and, when required by the paucity of controlled studies, from open-label clinical series. Anti-tumor necrosis factor (anti-TNF) and non-anti-TNF-targeted biologics approved for RA were investigated.ResultsADAb formation is chiefly associated with anti-TNFs, and it is reduced by combination therapy with methotrexate. To date, ADAb titration is not advisable for clinical practice, and, in case of anti-TNF secondary failure, a non-anti-TNF biologic is indicated. LLS is observed in anti-TNF receivers and, in most cases, resolves without anti-TNF withdrawal. A non-anti-TNF biologic is advisable in patients experiencing LLS. Non-anti-TNFs demonstrated a low or absent infection risk and are preferable in patients with comorbidities. Due to their positive effects on bone mass, anti-TNFs are indicated in women at osteoporosis risk, whereas non-anti-TNF have been poorly investigated. The emerging evidence of the relationship between RA and PD and the effects on anti-TNF efficacy should lead clinicians to consider the periodontal status in RA patients. Anti-TNFs may exert a positive effect on fertility and sexuality, and clinicians should explore these aspects in RA patients.ConclusionThe optimization of biologic therapies by taking into proper account the above issues would improve patient outcomes.

show abstract

Effectiveness of a systematic vaccination program in patients with autoimmune inflammatory disease treated with anti-TNF alpha drugs

Abstract: This vaccination program decreases infectious complications and was associated with a lower amount of hospital admissions due to infections, emergency room visits and the rate of invasive pneumococcal disease.

Cited by 9 publications

References 27 publications

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables

Contact Info

Product

Resources

About